Question 1

What is Ultragenyx Pharmaceutical's deferred tax assets?

Accepted Answer

Ultragenyx Pharmaceutical (RARE) reported deferred tax assets of $30M in Q2 2026.

Question 2

How has Ultragenyx Pharmaceutical's deferred tax assets changed year-over-year?

Accepted Answer

Ultragenyx Pharmaceutical's deferred tax assets decreased by 0.2% year-over-year, from $30.06M to $30M.

Question 3

What is the long-term trend for Ultragenyx Pharmaceutical's deferred tax assets?

Accepted Answer

Over 5 years (2020 to 2025), Ultragenyx Pharmaceutical's deferred tax assets has grown at a -2.1% compound annual growth rate (CAGR), from $33.31M to $30M.

Question 4

What does deferred tax assets mean?

Accepted Answer

Future tax benefits from temporary differences, net operating loss carryforwards, and tax credit carryforwards that will reduce future tax payments.

Line item	June 30, 2026	December 31, 2025
Liabilities for sales of future royalties	76	69
Other liabilities	15	19
Total current liabilities	351	384
Deferred tax liabilities	30	30
Liabilities for sales of future royalties	1,126	1,147
Other liabilities	41	44
Total liabilities	1,548	1,605
Noncontrolling interest	7	7

Deferred Tax Assets at other companies

Other financials

Income statement

Balance sheet

Cash flow

Valuation

Profitability

Returns & leverage

Where this comes from

FAQ

Ask your AI about Ultragenyx Pharmaceutical's deferred tax assets.

Ultragenyx Pharmaceutical RARE Deferred Tax Assets